

# Disclosures

# Personal Commercial (26)

| Company Name                              | Relationship Category                         | Compensation Level       | Topic Area(s)                                    |
|---|---|--------------------------|--|
| Self                                      |   |                          |  |
| Amgen                                     | Research/Research Grants                      | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies               |
| Amgen                                     | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies               |
| AstraZeneca                               | Research/Research Grants                      | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies<br>Prevention |
| AstraZeneca                               | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies<br>Prevention |
| Baxter Healthcare                         | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies               |
| Bayer AG                                  | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies<br>Prevention |
| Boehringer Ingelheim Pharmaceuticals, Inc | Research/Research Grants                      | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies<br>Prevention |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies<br>Prevention |
| Cytokinetics                              | Consultant Fees/Honoraria                     | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies               |
| Esperion                                  | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | General Cardiology                               |
| Fresenius Medical Care                    | Consultant Fees/Honoraria                     | Modest (< \$5,000)       | General Cardiology                               |
| Galmed                                    | Research/Research Grants                      | Modest (< \$5,000)       | Prevention                                       |
| Idorsia                                   | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | General Cardiology                               |
| Impulse Dynamics                          | Research/Research Grants                      | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies               |
| Lexicon Pharmaceuticals                   | Consultant Fees/Honoraria                     | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies<br>Prevention |
| Merck & Co., Inc.                         | Consultant Fees/Honoraria                     | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies               |
| Milestone Pharmaceuticals                 | Consultant Fees/Honoraria                     | Modest (< \$5,000)       | General Cardiology                               |
| Novartis Corporation                      | Research/Research Grants<br>‡ VICTORION-NOVEL | Significant (>= \$5,000) | Prevention                                       |
| Novartis Corporation                      | Speaker's Bureau                              | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies               |
| Occlutech                                 | Research/Research Grants                      | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies               |
| Recordati                                 | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies               |
| Relypsa                                   | Consultant Fees/Honoraria                     | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies               |
| Roche Diagnostics                         | Speaker's Bureau                              | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies               |
| Sanofi-Aventis                            | Research/Research Grants                      | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies               |
| Sanofi-Aventis                            | Consultant Fees/Honoraria                     | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies               |
| Tricog Health                             | Consultant Fees/Honoraria                     | Modest (< \$5,000)       | Heart Failure and Cardiomyopathies               |
|   |   |                          |  |

# Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

# Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

#### Institutional Financial Decision-Making Role (0)

No disclosures on record

#### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

### Agreement

Certified Education Attestation | Signed on 10/23/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/23/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 10/23/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/23/2025

#### **ACC** and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.